Stocks of Artivion Inc (NYSE:AORT) traded higher last session on Wall Street, up 5.55% to $16.75.
According to the data, Artivion Inc (NYSE:AORT) has 5 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $20.00, we find $25.00. Given the previous closing price of $15.87, this indicates a potential upside of 57.53 percent. AORT stock price is now 18.06% away from the 50-day moving average and 14.36% away from the 200-day moving average. The market capitalization of the company currently stands at $687.59M.
A total of 0 analysts have issued a hold rating and 5 have given it a buy rating. Brokers who have rated the stock have averaged $24.15 as their price target over the next twelve months.
With the price target reduced from $32 to $28, Lake Street maintained Buy rating for Artivion Inc (NYSE: AORT).
In other news, Getz Matthew A, VP, Human Resources sold 6,329 shares of the company’s stock on Jun 07. The stock was sold for $100,483 at an average price of $15.88. Upon completion of the transaction, the VP, Human Resources now directly owns 30,387 shares in the company, valued at $0.51 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 06, SVP, Operations Maier Dennis B sold 16,254 shares of the business’s stock. A total of $248,163 was realized by selling the stock at an average price of $15.27. This leaves the insider owning 34,724 shares of the company worth $0.58 million. Insiders disposed of 223,193 shares of company stock worth roughly $3.74 million over the past 1 year. A total of 5.00% of the company’s stock is owned by insiders.
Wednesday’s opening bell rang with an opening price of $16.34 for Artivion Inc (NYSE: AORT). During the past 12 months, Artivion Inc has had a low of $11.39 and a high of $17.97. As of last week, the company has a debt-to-equity ratio of 1.32, a current ratio of 3.96, and a quick ratio of 2.53. The fifty day moving average price for AORT is $14.19 and a two-hundred day moving average price translates $14.65 for the stock.
The latest earnings results from Artivion Inc (NYSE: AORT) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at -$0.24, missing analysts’ expectations of -$0.06 by -0.18. This compares to -$0.34 EPS in the same period last year. The net profit margin was -7.20% and return on equity was -9.28% for AORT. The company reported revenue of $87.85 million for the quarter, compared to $76.84 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.34 percent. For the current quarter, analysts expect AORT to generate $89.29M in revenue.
Artivion Inc(AORT) Company Profile
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
